Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ASBM Hits Back At British Columbia Switching Scheme

07 Jun 2019

• By Dave Wallace

Canada — ASBM Has Aimed Its Criticism At The Canadian Province • Source: Shutterstock

Related Content

UK expects to save 75% from adalimumab rivals

30 Nov 2018

England Expects Biosimilar Savings Of Up To Half A Billion

07 Jun 2019

British Columbia Starts Biosimilar Switching Program

29 May 2019

Additional Topics

Canada Regulation Biosimilars BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.